Should I buy or sell Repare Therapeutics stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RPTX shares. View RPTX analyst ratings or view top-rated stocks .

What is Repare Therapeutics' stock price target for 2024?

5 equities research analysts have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price targets range from $14.00 to $28.00. On average, they anticipate the company's stock price to reach $21.80 in the next year. This suggests a possible upside of 323.3% from the stock's current price. View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts .

How have RPTX shares performed in 2023?

Repare Therapeutics' stock was trading at $14.71 at the start of the year. Since then, RPTX stock has decreased by 65.0% and is now trading at $5.15. View the best growth stocks for 2023 here .

Are investors shorting Repare Therapeutics?

Repare Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 24.1% from the October 31st total of 1,740,000 shares. Based on an average daily trading volume, of 311,200 shares, the short-interest ratio is currently 6.9 days. Currently, 6.8% of the shares of the company are sold short. View Repare Therapeutics' Short Interest .

When is Repare Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024. View our RPTX earnings forecast .

How were Repare Therapeutics' earnings last quarter?

Repare Therapeutics Inc. (NASDAQ:RPTX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.41. The business had revenue of $2.16 million for the quarter, compared to analysts' expectations of $7.03 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 38.60% and a negative net margin of 173.09%.

What ETF holds Repare Therapeutics' stock ?

ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio.

What other stocks do shareholders of Repare Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA) , Marvell Technology (MRVL) , Adobe (ADBE) , Albertsons Companies (ACI) , Abbott Laboratories (ABT) , AES (AES) , Autodesk (ADSK) and

When did Repare Therapeutics IPO?

(RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.

Who are Repare Therapeutics' major shareholders?

Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (6.23%), Redmile Group LLC (5.71%), FMR LLC (2.56%), Sumitomo Mitsui Trust Holdings Inc. (0.77%), Harbor Capital Advisors Inc. (0.10%) and Trexquant Investment LP (0.07%). Insiders that own company stock include Ansbert Gadicke , Bvf Partners L P/Il, David P Bonita , Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal , Michael Zinda , Orbimed Advisors Llc, Thomas Civik and Todd Foley . View institutional ownership trends .

How do I buy shares of Repare Therapeutics?

Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Repare Therapeutics Stock Price, News & Analysis (NASDAQ:RPTX)

$5.15

-0.12 (-2.28%)

(As of 11/30/2023 ET)

Compare

Today's Range: $5.11
▼
$5.61
50-Day Range: $3.22
▼
$12.70
52-Week Range: $3.08
▼
$17.82

Volume: 792,469 shs
Average Volume: 173,316 shs
Market Capitalization: $216.97 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $21.80

Repare Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.80 Rating Score
Upside/Downside: 323.3% Upside
$21.80 Price Target
Short Interest: Bearish
6.79% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.51
Based on 5 Articles This Week
Insider Trading: Acquiring Shares
$7.48 M Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($1.99) to ($3.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.28 out of 5 stars

Medical Sector

328th out of 949 stocks

Pharmaceutical Preparations Industry

136th out of 435 stocks

3.4

Analyst's Opinion

Consensus Rating
Repare Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $21.80, Repare Therapeutics has a forecasted upside of 323.3% from its current price of $5.15.
Amount of Analyst Coverage
Repare Therapeutics has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
6.79% of the float of Repare Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Repare Therapeutics has a short interest ratio ("days to cover") of 6.9.
Change versus previous month
Short interest in Repare Therapeutics has recently increased by 24.14%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Repare Therapeutics does not currently pay a dividend.
Dividend Growth
Repare Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RPTX.

3.1

News and Social Media Coverage

News Sentiment
Repare Therapeutics has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Repare Therapeutics this week, compared to 1 article on an average week.
Search Interest
16 people have searched for RPTX on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
MarketBeat Follows
1 people have added Repare Therapeutics to their MarketBeat watchlist in the last 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Repare Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $7,479,132.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
28.50% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Repare Therapeutics are expected to decrease in the coming year, from ($1.99) to ($3.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Repare Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Repare Therapeutics is -2.23, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Repare Therapeutics has a P/B Ratio of 0.93. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Repare Therapeutics Stock (NASDAQ:RPTX)

Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.

RPTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

RPTX Stock News Headlines

November 24, 2023 | benzinga.com

Repare Therapeutics Stock (NASDAQ:RPTX) Earnings Dates and Earning Calls

November 24, 2023 | benzinga.com

Repare Therapeutics Stock (NASDAQ:RPTX) Dividends: History, Yield and Dates

November 30, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 23, 2023 | americanbankingnews.com

HC Wainwright Brokers Increase Earnings Estimates for Repare Therapeutics Inc. (NASDAQ:RPTX)

November 21, 2023 | markets.businessinsider.com

Promising Preclinical Data and Potential for Addressing Unmet Need Drive Buy Rating for Repare Therapeutics

November 21, 2023 | americanbankingnews.com

Repare Therapeutics (NASDAQ:RPTX) Given "Buy" Rating at HC Wainwright

November 20, 2023 | finance.yahoo.com

Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why

November 15, 2023 | finance.yahoo.com

Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor

November 30, 2023 | Tomorrow Investor (Ad)

The Only Practical Solution to the World’s Looming Energy Crisis

There’s just one problem: There are more plans for new uses of nuclear than there is uranium to fuel the plants!

November 12, 2023 | finance.yahoo.com

Repare Therapeutics Inc. (NASDAQ:RPTX) most popular amongst private equity firms who own 33% of the shares, institutions hold 28%

November 9, 2023 | benzinga.com

Recap: Repare Therapeutics Q3 Earnings

November 9, 2023 | finance.yahoo.com

Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results

November 9, 2023 | finance.yahoo.com

Repare Therapeutics Inc (RPTX) Reports Q3 2023 Financial Results Amid Pipeline Progress

November 7, 2023 | finance.yahoo.com

Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast

November 6, 2023 | msn.com

Repare Therapeutics 10% owner acquires stock worth ~$3M

November 5, 2023 | morningstar.com

Repare Therapeutics Inc Ordinary Shares RPTX

October 19, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Roche Holding AG (OtherRHHVF) and Repare Therapeutics (RPTX)

October 19, 2023 | markets.businessinsider.com

Stifel Nicolaus Keeps Their Buy Rating on Repare Therapeutics (RPTX)

October 17, 2023 | msn.com

Piper Sandler Maintains Repare Therapeutics (RPTX) Overweight Recommendation

October 13, 2023 | markets.businessinsider.com

Repare : Phase 1 Trial Of Lunresertib Combination Shows Clear Signals Of Anti-tumor Activity

October 13, 2023 | finance.yahoo.com

Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib

October 11, 2023 | finance.yahoo.com

Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround

October 9, 2023 | finance.yahoo.com

Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks

October 3, 2023 | finance.yahoo.com

Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

September 25, 2023 | msn.com

Stifel Maintains Repare Therapeutics (RPTX) Buy Recommendation

September 20, 2023 | finance.yahoo.com

Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?

September 19, 2023 | finance.yahoo.com

Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

See More Headlines

Receive RPTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/09/2023
Today: 11/30/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 2/27/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RPTX
CUSIP: N/A
CIK: 1808158
Web: www.reparerx.com
Phone: 857-412-7018
Fax: N/A
Employees: 180
Year Founded: 2016

Price Target and Rating

Average Stock Price Target: $21.80
High Stock Price Target: $28.00
Low Stock Price Target: $14.00
Potential Upside/Downside: +310.5%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.80
Research Coverage: 5 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.31)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-29,050,000.00
Net Margins: -173.09%
Pretax Margin: -163.40%
Return on Equity: -38.60%
Return on Assets: -30.25%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.62
Quick Ratio: 5.62

Sales & Book Value

Annual Sales: $131.83 million
Price / Sales: 1.70
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $5.54 per share
Price / Book: 0.96

Miscellaneous

Outstanding Shares: 42,130,000
Free Float: 30,123,000
Market Cap: $223.71 million
Optionable: Not Optionable
Beta: 0.09

Social Links

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

Mr. Lloyd Mitchell Segal (Age 59)
President, CEO & Director
Comp: $913.39k
Dr. Michael Zinda Ph.D. (Age 52)
Executive VP & Chief Scientific Officer
Comp: $641.53k
Dr. Maria Koehler M.D. (Age 66)
Ph.D., Executive VP & Chief Medical Officer
Comp: $682.8k
Dr. Daniel Durocher Ph.D.
Co-Founder
Dr. Frank Sicheri Ph.D.
Co-Founder
Dr. Agnel Sfeir Ph.D.
Co-Founder
Mr. Steve Forte (Age 44)
Executive VP & CFO
Comp: $608.52k
Mr. Daniel Belanger
Executive Vice President of Human Resource
Mr. Cameron Black
Executive Vice President of Discovery
Dr. Kim A. Seth Ph.D.
Executive VP & Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RPTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Repare Therapeutics stock right now?: 5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" RPTX shares.
View RPTX analyst ratings or view top-rated stocks.
What is Repare Therapeutics' stock price target for 2024?: 5 equities research analysts have issued 12 month price targets for Repare Therapeutics' stock. Their RPTX share price targets range from $14.00 to $28.00. On average, they anticipate the company's stock price to reach $21.80 in the next year. This suggests a possible upside of 323.3% from the stock's current price.
View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts.
How have RPTX shares performed in 2023?: Repare Therapeutics' stock was trading at $14.71 at the start of the year. Since then, RPTX stock has decreased by 65.0% and is now trading at $5.15.
View the best growth stocks for 2023 here.
Are investors shorting Repare Therapeutics?: Repare Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 2,160,000 shares, an increase of 24.1% from the October 31st total of 1,740,000 shares. Based on an average daily trading volume, of 311,200 shares, the short-interest ratio is currently 6.9 days. Currently, 6.8% of the shares of the company are sold short.
View Repare Therapeutics' Short Interest.
When is Repare Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 27th 2024.
View our RPTX earnings forecast.
How were Repare Therapeutics' earnings last quarter?: Repare Therapeutics Inc. (NASDAQ:RPTX) released its quarterly earnings data on Thursday, November, 9th. The company reported ($0.45) earnings per share for the quarter, topping analysts' consensus estimates of ($0.86) by $0.41. The business had revenue of $2.16 million for the quarter, compared to analysts' expectations of $7.03 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 38.60% and a negative net margin of 173.09%.

What ETF holds Repare Therapeutics' stock ?: ARK Genomic Revolution ETF holds 2,713,177 shares of RPTX stock, representing 0.98% of its portfolio.
What other stocks do shareholders of Repare Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and
When did Repare Therapeutics IPO?: (RPTX) raised $126 million in an IPO on Friday, June 19th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO.
Who are Repare Therapeutics' major shareholders?: Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include ARK Investment Management LLC (6.23%), Redmile Group LLC (5.71%), FMR LLC (2.56%), Sumitomo Mitsui Trust Holdings Inc. (0.77%), Harbor Capital Advisors Inc. (0.10%) and Trexquant Investment LP (0.07%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Thomas Civik and Todd Foley.
View institutional ownership trends.
How do I buy shares of Repare Therapeutics?: Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:RPTX) was last updated on 11/30/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial